{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lenvatinib","tislelizumab"]],"indication":"first-line advanced fumarate hydratase-deficient renal cell carcinoma","name":"NCT05877820","nct_id":"NCT05877820","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05877820. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive tislelizumab 200 mg intravenously every 3 weeks PLUS lenvatinib 20mg orally once daily.","label":"Tislelizumab+Lenvatinib combination therapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-12-31","type":"ACTUAL"},"conditions":["Fumarate Hydratase Deficient Renal Cell Carcinoma"],"enrollment":{"count":20,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tislelizumab","otherNames":[],"type":"BIOLOGICAL"},{"name":"Lenvatinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-10","lead_sponsor":"RenJi Hospital","official_title":"A Prospective, Single Arm Clinical Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in the First Line Treatment of Patients With Locally Advanced or Metastastic Fumarate Hydratase Deficient Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-12-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","timeFrame":"Up to approximately 24 months"}],"references":[{"citation":"Kong W, Xu Y, Liu G, Lv W, Wang Z, Cao D, Jiao F, Hu J, Wu X, Huang J, Chen Y, Zhai W, Wu X, Pan J, Huang Y, Wu G, Zheng L, Xue W, Zhang J. Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis. Nat Commun. 2026 Sep 7;17(1):10591. doi: 10.1038/s41467-026-77615-9.","pmid":"42844281","type":"DERIVED"}],"start_date":{"date":"2023-06-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC","url":"https://clinicaltrials.gov/study/NCT05877820"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05877820"}